Navigation Links
Isis Reports Financial Results and Highlights for First Quarter of 2008
Date:5/12/2008

ily led to the increase in Isis' consolidated working capital offset by $25 million of deferred revenue from Genzyme that is included in current liabilities. In connection with the Genzyme transaction, Isis recorded the $100 million premium on the $150 million equity investment as a liability and is amortizing it into revenue over the four-year period of the collaboration beginning in the first quarter of 2008. Isis recorded the remaining $50 million of proceeds as stockholders' equity.

Quarterly Highlights

"The momentum we created in 2007 continued in full force into the first quarter of 2008 with more partnering successes and advances in our pipeline. The highlight of the quarter was our strategic relationship with Genzyme focused on the licensing of mipomersen and a research relationship. Together with Genzyme, we have made significant progress in revising mipomersen's development plans to be responsive to the FDA's recent guidance. We remain confident the deal will be completed this quarter on terms that are attractive to both companies," continued Ms. Parshall. "As evidenced from our recent partnering successes, we continue to benefit from our business strategy that enables us to discover and develop drugs and technologies, nurturing them until the right time to progress them to partners or to satellite companies. This strategy has provided us with the financial strength and the diverse pipeline of drugs that we have today. Looking forward, we expect to grow our pipeline this year, adding two to four new drugs; already we have added the first drug with PSCK9, our development candidate with Bristol-Myers Squibb. In addition, we will be presenting clinical data from some of our most advanced drugs and moving exciting new drugs into clinical studies. We are on target to meet our financial goals for 2008, including ending the year with over $450 million in cash that will enable us to continue to exploit our efficient drug discovery platform and to lea
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles criminal ... recently spoke on the radio to give his insights into ... Independent Journal Review radio show “The Right Mics” chose Chambers ... and now as a criminal defense attorney would provide him ... and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, H1 2015? ... Alopecia is the loss of hair. Alopecia areata and ... Causes for alopecia include aging, genetics, illness, chemotherapy, malnutrition ... pattern hair loss, female diffuse hair loss, hairs easily ... focal or diffuse and by the presence or absence ...
(Date:3/3/2015)... Houston, TX (PRWEB) March 03, 2015 ... sponsored by the National Sleep Foundation. The event brings ... the world over. , According to the ... ongoing sleep problems of one form or another. Too ... a greater risk of physical illness and depression, and ...
(Date:3/3/2015)... The combinatorial, multi-gene GeneSight test has ... for patients with depression, and their use of ... genes that comprise the test, according to a ... and Assurex Health, and published online by The ... of the GeneSight Psychotropic test is based on ...
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
Breaking Medicine News(10 mins):Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... 21 countries, reserachers have found that blood pressure levels across ... not go down in all of the populations, but it ... led the World Health Organization MONICA study conducted between 1980s ... did appear to have a cross- population effect. Most importantly, ...
... overseas-trained doctor, Farid Zaer, who has registered himself as ... Queensland, to continue his medical practice.// The doctor has ... accused for wrong diagnosis involving nearly 208 patients. ... as a GP, without any restriction or supervision. Under ...
... African American children deteriorate as they progress through puberty, ... of Alberta//. The levels of insulin, however, remain unchanged ... phase of growth plays a crucial role in determining ... 7-year, Alabama based study was conducted by Dr. Geoff ...
... to tackle the global threat from bird flu, it ... is felt that// it may provide the best help ... up such a system has been published in the ... through co-ordination between such international labs can warn the ...
... pregnancy can reduce the incidence of pregnancy complications, ... by American Journal of Obstetrics and Gynecology. ... blood pressure and proteinuria (high levels of protein ... and legs is usually seen. If left unattended, ...
... In an attempt to spread awareness about AIDS/HIV, the ... the State organized a health awareness program// ('One step ... targeted specifically at barbers. ,The local barbers, ... rally. A special AIDS/HIV awareness session was conducted at ...
Cached Medicine News:Health News:Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered 2Health News:African American Children More Pone to Develop Diabetes 2
(Date:3/3/2015)... March 3, 2015   ... 240 patients respectively Publications in peer reviewed ... Clinical Gastroenterology highlight diagnostic value of confocal laser ... China and across Asia ... (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal ...
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ) has announced ... 2015-2019" report to their offering. , ... to grow at a CAGR of 8.47 percent over ... IVD devices and tools used for diagnosing diseases in ... these devices helps in the rapid diagnosis of the ...
(Date:3/3/2015)... WAYNE, N.J. , March 3, 2015 ... USA announced today a new, integrated ... new portable solution is now available with a larger ... integrated console mounted system offers a larger viewing area ... console now provides additional space for accessories and storage, ...
Breaking Medicine Technology:Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 3
... Safety and Reduce Health Care CostsBETHESDA, Md., May 7 ... pilot program, contributing data on adverse events associated with ... will be possible to identify best practices that can ... overall costs to the health care system.This pilot hemovigilance ...
... Society Annual Meeting-BALTIMORE, May 7 Arcion Therapeutics, ... that develops pain therapies, today announced the presentation ... significantly reduced pain caused by diabetic neuropathy in ... presented in a poster session on May 8th ...
Cached Medicine Technology:National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 2Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: